Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046384 · ClinicalTrials.gov registry record · Phase 3
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00046384: Completed Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT00046384 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00046384, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to learn if aripiprazole is effective in the treatment of patients with acute symptoms of Bipolar Disorder.
Interventions
- DRUG aripiprazole
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-06 |
| Est. Completion | 2003-04 |
| Phase | Phase 3 |
What the finished NCT00046384 record still lists
NCT00046384 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which aripiprazole is the first listed.
NCT00046384 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00046384 about?
NCT00046384 is a clinical study titled "Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder". The purpose of this study is to learn if aripiprazole is effective in the treatment of patients with acute symptoms of Bipolar Disorder.
What is the current status of trial NCT00046384?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-06. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00046384?
The interventions under investigation include: aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00046384?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia